Vaxcyte (PCVX) closed at $63.89 on November 6, 2026, up 3.2% from the previous close, on volume of 1,741,436 shares (30-day average 3,160,669).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 19, 2026 | Put with Delta Hedge | 20-Nov-26 60 P +29,368 Stock | 1,020 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
TipRanks (Thu, 5-Nov 6:20 PM ET)
Leerink Partners Reaffirms Their Buy Rating on Vaxcyte (PCVX)
TipRanks (Thu, 5-Nov 9:29 AM ET)
TD Cowen Remains a Buy on Vaxcyte (PCVX)
TipRanks (Thu, 5-Nov 9:08 AM ET)
BTIG Sticks to Their Buy Rating for Vaxcyte (PCVX)
TipRanks (Thu, 5-Nov 6:16 AM ET)
Vaxcyte GAAP EPS of -$1.99 beats by $0.15
Seeking Alpha News (Wed, 4-Nov 5:46 PM ET)
Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update
Globe Newswire (Wed, 4-Nov 4:05 PM ET)
Globe Newswire (Fri, 9-Oct 4:05 PM ET)
Vaxcyte Prices $1 Billion Financing Mix as VAX-31 Clinical and Launch Spending Ramps
Market Chameleon (Wed, 7-Oct 5:26 AM ET)
Globe Newswire (Tue, 6-Oct 10:48 PM ET)
Globe Newswire (Mon, 5-Oct 4:28 PM ET)
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
Vaxcyte trades on the NASDAQ stock market under the symbol PCVX.
As of November 6, 2026, PCVX stock price climbed to $63.89 with 1,741,436 million shares trading.
PCVX has a beta of 1.06, meaning it tends to be more sensitive to market movements. PCVX has a correlation of 0.08 to the broad based SPY ETF.
PCVX has a market cap of $10.11 billion. This is considered a Large Cap stock.
In the last 3 years, PCVX traded as high as $121.06 and as low as $27.66.
The top ETF exchange traded funds that PCVX belongs to (by Net Assets): VTI, IWM, VB, XBI, VBK.
PCVX has outperformed the market in the last year with a price return of +53.2% while the SPY ETF gained +10.8%. PCVX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +8.5% and +5.7%, respectively, while the SPY returned -4.1% and -3.2%, respectively.
PCVX support price is $59.72 and resistance is $64.12 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PCVX shares will trade within this expected range on the day.
